Can you interpret the laboratory results for an 83‑year‑old patient with mild normocytic anemia, low mean corpuscular hemoglobin concentration, reactive thrombocytosis, borderline high neutrophil count, and reduced renal function consistent with stage 3 chronic kidney disease?

Laboratory Interpretation for 83-Year-Old Patient

This patient has anemia of chronic kidney disease (CKD stage 3b) with likely functional iron deficiency, reactive thrombocytosis from chronic inflammation or iron deficiency, and a mild neutrophilia suggesting underlying inflammatory stress.

Key Abnormalities Identified

1. Stage 3b Chronic Kidney Disease

• eGFR 45 mL/min/1.73m² with creatinine 1.19 mg/dL confirms CKD stage 3b 1
• This level of renal impairment is the primary driver of anemia in this patient 2
• CKD becomes a likely cause of anemia when GFR <60 mL/min/1.73m², and especially when <30 mL/min/1.73m² 2

2. Normocytic Anemia

• Hemoglobin 10.0 g/dL (low), Hematocrit 32.1% (low), RBC 3.52 (low)
• MCV 91 fL = normocytic pattern 3
• This normocytic anemia is characteristic of CKD-related anemia 4
• The primary mechanism is insufficient erythropoietin production by diseased kidneys 4

3. Low MCHC (31.2 g/dL)

• Suggests either functional iron deficiency or early absolute iron deficiency 3
• Critical finding: Low MCHC in CKD patients has been associated with increased cardiovascular risk, particularly non-atherosclerotic CVD, left ventricular hypertrophy, and left atrial overload 5
• This parameter is more stable than MCV or MCH and may predict adverse cardiovascular outcomes 5

4. Reactive Thrombocytosis (516 x10³/μL)

• Elevated platelets commonly occur with iron deficiency or chronic inflammation 6
• In the context of anemia, this suggests either iron deficiency or inflammatory response
• Not associated with primary hematologic malignancy given normal WBC differential

5. Borderline Neutrophilia

• Absolute neutrophils 7.6 x10³/μL (slightly elevated)
• Immature granulocytes 1% with absolute count 0.1 (upper limit of normal)
• Suggests mild inflammatory state or physiologic stress response
• Common in CKD due to chronic inflammation 2

Required Additional Workup

You must obtain iron studies immediately 3, 7, 8:

• Serum ferritin (target >100 ng/mL in non-dialysis CKD) 2
• Transferrin saturation (TSAT) (target >20% in CKD) 2
• These define whether absolute vs. functional iron deficiency exists

Additional essential tests 3, 7:

• Reticulocyte count (absolute) - to assess bone marrow response
• Vitamin B12 and folate levels - rule out nutritional deficiencies
• Consider: Stool guaiac testing if iron deficiency confirmed (GI blood loss evaluation) 2

Clinical Significance & Management Approach

Anemia Management Algorithm:

1. First: Establish iron status 2

   • If TSAT ≤20% and ferritin ≤100 μg/L = absolute iron deficiency
   • If TSAT ≤20% with ferritin >100 μg/L = functional iron deficiency
   • Both are common in CKD and require treatment

2. Iron Replacement Strategy 2, 7:

   • Oral iron trial (1-3 months) acceptable in non-dialysis CKD if tolerated
   • Intravenous iron preferred if oral not tolerated or ineffective
   • Target: TSAT >20% and ferritin >100 ng/mL before considering ESA therapy 9

3. ESA Therapy Consideration 7, 9:

   • Only after optimizing iron status
   • For Hb <10.0 g/dL, individualize decision based on:
     • Symptoms (fatigue, dyspnea, reduced functional capacity)
     • Rate of Hb decline
     • Transfusion risk
     • Cardiovascular history (use caution if prior stroke or active malignancy) 7
   • Target Hb: 11.0-12.0 g/dL (not higher due to cardiovascular risks) 9

4. Nephrology Referral Indicated 2:

   • CKD stage 3b with symptomatic anemia requires specialist co-management
   • Complex interplay of erythropoietin deficiency, iron metabolism, and inflammation

Critical Pitfalls to Avoid

• Do not assume anemia is "just from CKD" without checking iron studies, B12, and folate 3, 7, 8
• Do not start ESA therapy before correcting iron deficiency - this leads to ESA hyporesponsiveness 7, 9
• Do not target Hb >12.0 g/dL with ESAs - increases stroke, thrombosis, and mortality risk 7, 9
• Do not ignore the low MCHC - monitor cardiovascular status given association with LVH and adverse outcomes 5
• Consider GI evaluation if absolute iron deficiency confirmed, even in CKD patients 2

Other Laboratory Findings

• Glucose 96 mg/dL: Normal, no diabetes evident
• Electrolytes, calcium, liver function: All normal
• No evidence of: Infection, hemolysis, or primary bone marrow disorder based on differential and other parameters